Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

584 questions · 593 findings · 51 reviews · Airways

No studies found 37 · 6.2%GRADE not reported 40 · 6.7%Very low 44 · 7.4%Low 172 · 29%Moderate 232 · 39.1%High 68 · 11.5%

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause mortality ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/budesonide vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in asthma‐related non‐fatal serious adverse events ‐… compared with salmeterol/ICS (low certainty).

5 findings from 1 review
Show 2 more findings

Children: formoterol/fluticasone vs regular salmeterol and fluticasone

Non‐fatal serious adverse events · children with chronic asthma

Children: formoterol/fluticasone showed no clear difference in all‐cause non‐fatal serious adverse events compared with salmeterol/fluticasone (low certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal SAE ‐ Adults · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐… compared with salmeterol/ICS (moderate certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/mometasone… compared with salmeterol/ICS (moderate certainty).

1 finding from 1 review

Adults: formoterol/ICS vs salmeterol/ICS

All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality

Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone… compared with salmeterol/ICS (low certainty).

1 finding from 1 review

Regular formoterol and ICS vs same‐dose ICS

Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality

Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).

1 finding from 1 review